Amgen
Registered Principal Details
Business Or Interest:
Pharmaceutical manufacturing
Lobbying Interests:
All matters relating to the pharmaceuticals and health care industries
CEO Name:
Robert Bradway
Executive Director
Pharmaceutical manufacturing
Lobbying Interests:
All matters relating to the pharmaceuticals and health care industries
CEO Name:
Robert Bradway
Executive Director
Contact
KS
Kathy Sherman
601 13th Street, NW, 12th Floor
Washington, DC 20005
(202) 585-9614
(202) 585-9729
kathy.sherman@amgen.com
601 13th Street, NW, 12th Floor
Washington, DC 20005
(202) 585-9614
(202) 585-9729
kathy.sherman@amgen.com
Authorized Lobbyists
| Lobbyist Name | Exclusive Duties | Authorized On | Withdrawn On |
|---|
Lobbying Interests
Legislative Bills/Resolutions
Assembly Bill 679
Relating to: the treatment of biological products for various purposes under the pharmacy practice law.
Bill Text and History
12/12/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: the treatment of biological products for various purposes under the pharmacy practice law.
Bill Text and History
For
Notification Date12/12/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Senate Bill 575
Relating to: the treatment of biological products for various purposes under the pharmacy practice law.
Bill Text and History
2017 Wisconsin Act 149
12/12/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Relating to: the treatment of biological products for various purposes under the pharmacy practice law.
Bill Text and History
2017 Wisconsin Act 149
For
Notification Date12/12/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Topics Not Yet Assigned A Bill Or Rule Number
Development, drafting or introduction of a proposal relating to
Substitution of interchangeable biosimilars
Substitution of interchangeable biosimilars
Action Intended To Affect
Both Legislative matter and rule
Notification Date
7/19/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Both Legislative matter and rule
Notification Date
7/19/2017
First Communication Date
N/A
Communication Information
The principal, a lobbyist authorized by the principal, or another individual acting on behalf of the principal do not intend to communicate on this matter.
Total Lobbying Effort
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total | |
|---|---|---|---|---|---|
| Total Lobbying Expenditures | 2017 January - June $0.00 |
2017 July - December $7,117.61 |
2018 January - June $12,000.00 |
2018 July - December $440.67 |
Total $19,558.27 |
| Total Hours Communicating | 2017 January - June 0.00 |
2017 July - December 4.00 |
2018 January - June 9.00 |
2018 July - December 0.00 |
Total 13.00 |
| Total Hours Other | 2017 January - June 0.00 |
2017 July - December 35.00 |
2018 January - June 23.50 |
2018 July - December 3.50 |
Total 62.00 |
Percent Allocation of Lobbying Effort
Legislative Bills/Resolutions
Relating to: the treatment of biological products for various purposes under the pharmacy practice law.
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June |
2017 July - December 30% |
2018 January - June 40% |
2018 July - December |
Total 33% |
Relating to: the treatment of biological products for various purposes under the pharmacy practice law.
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June |
2017 July - December 30% |
2018 January - June 60% |
2018 July - December |
Total 43% |
Budget Bill Subjects
No budget bill subjects found.
Administrative Rulemaking Proceedings
No administrative rulemaking proceedings found.
Topics Not Yet Assigned A Bill Or Rule Number
| 2017 January - June |
2017 July - December |
2018 January - June |
2018 July - December |
Total |
|---|---|---|---|---|
| 2017 January - June |
2017 July - December 40% |
2018 January - June |
2018 July - December |
Total 21% |
Minor Efforts
No minor efforts found.
Other Matters
Includes time spent on:
- Gubernatorial nominations
- Matters on which the organization made no lobbying communication